FABP4 Monoclonal antibody, PBS Only

FABP4 Monoclonal Antibody for WB, IHC, Indirect ELISA
Cat No. 67167-1-PBS
Clone No.3E7E1

Host / Isotype

Mouse / IgG2b

Reactivity

Human, mouse, rat, pig

Applications

WB, IHC, Indirect ELISA

A FABP, AFABP, ALBP, aP2, FABP4, Fatty acid binding protein 4

Formulation:  PBS Only
PBS and Azide
PBS Only
Conjugate:  Unconjugated
Size/Concentration: 

-/ -

Freight/Packing: -

Quantity

Please visit your regions distributor:


Product Information

67167-1-PBS targets FABP4 in WB, IHC, Indirect ELISA applications and shows reactivity with Human, mouse, rat, pig samples.

Tested Reactivity Human, mouse, rat, pig
Host / Isotype Mouse / IgG2b
Class Monoclonal
Type Antibody
Immunogen FABP4 fusion protein Ag8565 Predict reactive species
Full Name fatty acid binding protein 4, adipocyte
Calculated Molecular Weight 132 aa, 15 kDa
Observed Molecular Weight 14 kDa
GenBank Accession NumberBC003672
Gene Symbol FABP4
Gene ID (NCBI) 2167
RRIDAB_2882463
Conjugate Unconjugated
Form Liquid
Purification MethodProtein A purification
UNIPROT IDP15090
Storage Buffer PBS Only
Storage ConditionsStore at -80°C.

Background Information

Fatty acid binding protein (FABP) 4 is a member of the FABP family which abundantly expressed, fatty acid carrier proteins. FABPs are capable of binding a variety of hydrophobic molecules such as long-chain fatty acids and are important for their uptake and intracellular trafficking. It was first identified as an adipocyte-specific protein, important for the maintenance of lipid and glucose metabolism. It is also detected in macrophages, where it participates in regulating inflammation and cholesterol trafficking via NFκB and PPAR. In more recent studies, FABP4 has been found in a variety of endothelial cells, where it has been identified as a target of VEGF and a regulator of cell proliferation and possibly angiogenesis. Pathologically, FABP4 has been associated with the development of metabolic syndrome, diabetes and cancer and vulnerability of atherosclerotic plaques. FABP4 has been identified as a novel prognostic factor for both adverse cardiovascular events and breast cancer.

Loading...